Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Ranolazine Extended Release Tablets (US RLD- Ranexa), 500 mg and 1.000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. It will be manufactured at the group’s formulations manufacturing facility at Baddi.
The group now has 271 approvals and has so far filed over 360 ANDAS since the commencement of the filing process in FY 2003 -04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.